Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma

Background The INTEGRATE phase II multinational randomized controlled trialdemonstrated the activity of regorafenibon progression-free survival(PFS) in patients with refractory advanced gastric adenocarcinoma. We sought to evaluate whether these PFS gains had the potential to be offset by quality of life (QoL) impacts from treatment side effects and to thereby determine the appropriateness of continuing development to phase III.